22nd Annual Scientific Sessions:
Shedding Light on Emerging Metabolic Targets in Cardiovascular Diseases
Bordeaux, France 22-25 June 2025
22nd Annual Scientific Sessions:
Shedding Light on Emerging Metabolic Targets in Cardiovascular Diseases
Bordeaux, France 22-25 June 2025
22nd Annual Scientific Sessions:
Shedding Light on Emerging Metabolic Targets in Cardiovascular Diseases
Bordeaux, France 22-25 June 2025
11:00-18:30 |
Registration [Hotel Lobby] |
10:00-12:00 |
SHVM Board Meeting (for board members only) |
13:00-16:30 |
Professional Development Session Chairs: Kaitlyn Dennis (Oxford University, UK) and Mark Pepin (Harvard Medical School, USA) |
13:00-13:30 |
Christoph Dieterich (Heidelberg University, Germany) |
13:30-14:00 |
Gwang Lee (Ajou University, Republic of Korea) |
14:00-14:45 |
AI panel discussion Jai Hari Rajendran (Oklahoma State University, USA), Christoph Dieterich (Heidelberg University, Germany), Gwang Lee (Ajou University, Republic of Korea) |
14:45-15:15 |
Coffee break |
15:15-15:45 |
Meet the Editor Gregory Lim (Chief Editor, Nature Reviews Cardiology) |
15:45-16:15 |
Tristan Richard (Bordeaux University, France) |
16:15-17:00 |
Round table discussion: career advices from establised investigators and industry sponsors Linda R. Peterson, Christine des Rosiers, Mathieu Riuz, Dale Abel, Adam Wende, Adrienne Clements-Egan |
17:00-18:00 |
Speed dating Trainees / Established Investigators / Sponsors |
Opening Session |
|
18:00-18:15 |
Welcome from Organisers and SHVM President |
18:15-19:30 |
Keynote Lecture Chair: Dale Abel (University of California Los Angeles, USA) Sihem Boudina (University of Utah, USA) |
19:30-23:00 |
Informal dinner reception and networking [The Radisson Blu / Lawton restaurant] |
8:00-13:00 |
Registration [Hotel Lobby] |
6:30-7:30 |
Optional Run/Walk (~1-3 mi / ~1.6-5 km) – Quais de Bordeaux (near hotel) |
7:00-8:30 |
Breakfast |
8:30-9:30 |
Keynote Lecture Chairs: Christine des Rosiers (Montreal Heart Institute, Canada) and Pierre Dos Santos (Bordeaux University, France) Rong Tian (University of Washington, USA) |
Session 1 • Targeting Metabolism: Right Ventricular (RV) Dysfunction & Pulmonary hypertension (PHT) |
|
9:30-10:00 |
Christelle Guibert (Bordeaux University, France) |
10:00-10:30 |
Stephen Archer (Queen's University, Canada) |
10:30-11:00 |
Coffee break |
11:00-11:30 |
Sung Joon Kim (Seoul National University, Republic of Korea) |
11:00-11:15 |
Short talk: Akshay Shekhar (Regeneron Pharmaceuticals, NY, USA) |
11:15-11:30 |
Short talk: Yasutomi Higashikuni (Jichi Medical University, Japan) |
12:00-13:00 |
Lunch and networking |
13:00-13:30 |
MSD Sponsored Lecture |
Session 2 • Targeting Metabolism in Cardiac Arrhythmias Chairs: Florin Despa (Kentucky University, USA) and Kim Mellor (University of Auckland, New Zealand) |
|
13:30-14:00 |
Anuradha Kalyanasundaram (University of North Texas Health Sciences Center, USA) |
14:00-14:30 |
Jin Li (University of Bern, Switzerland) |
14:30-15:00 |
Philippe Pasdois (Bordeaux University, IBGC, France) |
15:00-15:15 |
Short talk: Bernadin Ndongson Dongmo (University of Oslo, Norway) |
15:15-15:30 |
Short talk: Julie Rennison (Cleveland Clinic, OH, USA) |
15:30-16:00 |
Coffee break |
16:00-17:00 |
Session 3 • The “William C. Stanley” Early Investigator Awards Chair: Linda R. Peterson (Washington University, USA) Four 15-min presentations from trainee awardees selected from submitted abstracts |
16:00-16:15 |
Satoshi Bujo (University of Cambridge, United Kingdom) |
16:15-16:30 |
Chloé David (Montreal Heart Institute, Canada) |
16:30-16:45 |
Natasha Nambiar (Max Delbruck Centre for Molecular Medicine, Germany) |
16:45-17:00 |
Ríona Devereux (University of Oxford, United Kingdom) |
17:00-19:00 |
Poster Session I / Exhibitions |
19:30-23:30 |
Dinner and networking – La Cité du Vin |
8:00-10:30 |
Registration [Hotel Lobby] |
7:00-8:30 |
Breakfast |
Session 4 • Targeting Metabolism: From Embryos to Cardiac Organoids Chairs: Benjamin Lauzier (Nantes University, France) and Petra Kienesberger (Dalhousie University, Canada) |
|
8:30-9:00 |
Magali Théveniau-Ruissy (Aix-Marseille University, France) |
9:00-9:30 |
Anna Zoccarato (King's College London, UK) |
9:30-10:00 |
Daan van Aalten (Aarhus University, Denmark) |
10:00-10:15 |
Short talk: Louis Berillon (University of Montreal, Canada) |
10:15-10:30 |
Short talk: Konstantinos Lekkos (University of Oxford, United Kingdom) |
10:30-12:30 |
Poster Session II / Exhibitions (with coffee and refreshments) |
12:30-13:30 |
Lunch and networking |
Session 5 • Targeting Metabolism in Heart Failure with Preserved Ejection Fraction (HFpEF) Chair: Soon-Jun Hong (Korea University, Republic of Korea) and Motohiro Nishid (Kyushu University, Japan) |
|
13:30-14:00 |
Kavita Sharma (John Hopkins School of Medicine, USA) |
14:00-14:30 |
Aldons Lusis (University of California Los Angeles, USA) |
14:30-15:00 |
Gabriele Schiattarella (Max Delbrück Center, Berlin, Germany) |
15:00-15:30 |
Coffee break |
15:30-16:00 |
Novo Nordisk Sponsored Lecture |
16:00-16:15 |
Short talk: Bellina Mushala (University of Pittsburgh, PA, USA) |
16:15-16:30 |
Short talk: Seema Mital (University of Toronto, Canada) |
17:00-19:00 |
Discover Le Bassin des Lumieres |
19:30-23:00 |
Gala Dinner - Le Café Maritime |
7:00-8:30 |
Breakfast |
8:30-9:30 |
"William C. Stanley" Award Lecture Chairs: Véronique Lacombe (Oklahoma State University, USA) and Mathias Mericskay (Paris-Saclay University, France) Christoph Maack (University Clinic Würzburg, Germany) |
Session 6 • Targeting Immunometabolism |
|
9:30-10:00 |
Edward Thorp (Northwestern University, USA) |
10:00-10:15 |
Short talk: Stefan Gross (University Medicine Greifswald, Germany) |
10:15-10:30 |
Short talk: Anne Hafstad (UiT-The Arctic University of Norway, Norway) |
10:30-11:00 |
Coffee break |
Session 7 • Targeting Iron Metabolism |
|
11:00-11:30 |
Larimar Therapeutic Sponsored Lecture Adrienne Clements-Egan & Christine Des Rosiers |
11:30-12:00 |
Lin Liu (Oklahoma State University, USA) |
12:00-12:30 |
Jean-Sébastien Joyal (Montreal University, Canada) |
12:30-12:45 |
FUJIFILM VisualSonics Sponsored Lecture |
12:45-13:00 |
Invitation to SHVM 2026 Japan |
13:00-13:30 |
Box Lunch |
Session 8 • Korea BCS and SHVM Chairs: Hyoung Kyu Kim (Inje University, Republic of Korea) and Fanny Vaillant (Bordeaux University, France) |
|
13:30-13:50 |
Jin Han (Inje University, Republic of Korea) |
13:50-14:10 |
Romain Capoulade (Nantes University, France) |
14:10-14:30 |
Kyu-Sang Park (Yonsei University Wonju, Republic of Korea) |
14:30-14:50 |
Jérôme Piquereau (Paris-Saclay University, France) |
14:50-15:00 |
Concluding Remarks Organizers and SHVM President |
When preparing your poster, please remember that its maximum size is A0 (841 x 1189 mm; width x height). Note that the orientation is portrait, not landscape.
Correct format...
Wrong format...
Poster presenters are required to be available for discussion during their assigned session. The distribution of posters in the two sessions is indicated below.
Posters in Session I (Monday, 23 June, 17:00-19:00) can be set up as early as Sunday evening or on Monday morning, before the first coffee break. These posters should be taken down on Monday evening. Any posters from this session that are still up by Tuesday at 08:00 will be discarded by the venue personnel so that the posters for Session II can be set up.
Posters in Session II (Tuesday, 24 June, 10:30-12:30) should be set up on Tuesday morning, in time for the session. These posters should be taken down only on Wednesday morning. Posters left behind after the conclusion of the meeting will be discarded by the venue personnel.
P1.1 · Yong Joo Ahn (Pohang, Republic of Korea)
Spatial analysis of the composition of human thrombus in acute ischemic stroke
P1.2 · Michelle Alff (Essen, Germany)
The dual role of red blood cells in cardioprotection by remote ischemic conditioning: reduction of myocardial infarct size and coronary no-reflow
P1.3 · Zach Kittle (Stillwater, OK, U.S.A.)
SARS-COV-2 Infection induces metabolic alterations in the cardiorespiratory system
P1.4 · Hugues Boel (Montreal, Canada)
Transcriptomic and lipidomic modulation by EZH2 inhibition in two models of experimental heart failure?
P1.5 · Anne Cathrine Furuheim Bryn (Tromsø, Norway)
Trastuzumab and anthracycline therapy alters intermediary metabolism the myocardium
P1.6 · Gael G.C. Cagnone (Montreal, Canada)
Metabolic reprogramming of the neovascular niche promotes regenerative angiogenesis in proliferative retinopathy.
P1.7 · Kaitlyn Dennis (Oxford, United Kingdom)
ACC and AMPK are post-translationally S-acylated, which is increased by low-flow ischemia
P1.8 · Matthieu Douard (Pessac, France)
Basal O-GlcNAcylation is essential to ensure proper electrical activity and calcium handling in rat cardiomyocytes
P1.9 · Chantal Eickelmann (Essen, Germany)
More Drp1 in endothelial cells – increased microvascular damage after ischemia/reperfusion injury: a study in isolated perfused rat hearts with endothelium-specific overexpression of Drp1
P1.10 · Claire Fong-McMaster (Ottawa, Canada)
Complexome profiling identifies changes in mitochondrial supercomplexes in murine heart failure
P1.11 · Stefan Gross (Greifswald, Germany)
Rationale and design of DEEP-HEART - Longitudinal cohort for deep phenotyping of study participants with and without heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), Greifswald, Germany
P1.12 · Bastien Guillot (Pessac, France)
Succinate metabolism remodelling is an actor of the transition from paroxysmal to persistent atrial fibrillation
P1.13 · Jin Han (Busan, Republic of Korea)
Unraveling the role of cereblon in cardiac aging: insights from a cardiac-specific deletion model in mice
P1.14 · Lisa Heather (Oxford, United Kingdom)
Multiomics-based assessment of 2D/3D human iPSC-cardiomyocyte models of insulin resistance recapitulate diabetic cardiomyopathy
P1.15 · Lorenz M.W. Holzner (Cambridge, United Kingdom)
Impacts of early life stress on bioenergetic function in the rat heart – a pilot study
P1.16 · Xin Hu (Amsterdam, Netherlands)
Empagliflozin’s protection against in vivo heart failure associates with early SGLT2-independent cardiac changes in transcriptomics and metabolic, but not mechanical, properties of the ex vivo heart
P1.17 · Yumiko Imai (Daito City, Osaka, Japan)
Age-related cellular dysregulation in a mouse model of post-intensive care syndrome
P1.18 · Ezra B. Ketema (Edmonton, Canada)
Cardiomyocyte SIRT2 deletion impairs glycolysis via hyperacetylation of glycolytic enzymes
P1.19 · Tobias Klose (Jena, Germany)
Metabolomic screening identifies novel toxins as potential biomarkers for uremic cardiomyopathy
P1.20 · Keiji K. Kuba (Fukuoka, Japan)
CNOT6L deadenylase suppresses cardiac remodeling in heart failure through downregulation of tenascin-C mRNA in fibroblasts
P1.21 · Wei Liu (Manchester, United Kingdom)
Blockage of lipotoxicity in cardiomyocytes attenuates heart failure in diabetes
P1.22 · Kim M Mellor (Auckland, New Zealand)
Augmented cardiac glycophagy accelerates cardiomyocyte Ca2+ reuptake and remediates diastolic dysfunction in a setting of metabolic stress
P1.23 · Tien Dung Nguyen (Jena, Germany)
Glucagon-like Peptide 1 based treatments preserve left ventricular diastolic function - A systematic review and meta-analysis
P1.24 · Atsuko Okazaki (Tokyo, Japan)
Deciphering metabolic drivers in pediatric mitochondrial cardiomyopathy: A 20-Year multi-omics approach to therapeutic target discovery
P1.25 · Gonen Ozsarlak-Sozer (Izmir, Turkey)
Empagliflozin exerts its effects targeting ER stress in diabetic cardiomyopathy: Is there a role for SIRT1?
P1.26 · Mikko Parkkonen (Oulu, Finland)
MicroRNA editing in primary myocardial fibrosis
P1.27 · Linda R. Peterson (St. Louis, MO, U.S.A.)
Gnostic trial: the nanodroplet oxygen delivery (NanO2™) for ST-elevation myocardial infarction
P1.28 · Annelise Poss (Durham, NC, U.S.A.)
Targeting succinyl-CoA metabolism: ALA supplementation and ketolysis in pressure-overloaded hearts
P1.29 · Mario Schubert (Dresden, Germany)
Advanced mitochondrial development is crucial for modeling myocardial infarction using human induced pluripotent stem cell-derived cardiomyocytes
P1.30 · Tanin Shafaati (Edmonton, Canada)
Systemic GIP receptor activation induces diastolic dysfunction in mice with type 2 diabetes
P1.31 · Nikola Srnic (Oxford, United Kingdom)
Unsaturated compared to saturated fatty acids improve in vivo human cardiac energetics, systolic, and diastolic function and are associated with upregulated fatty acid oxidation in human cardiomyocytes
P1.32 · Anna Strano (Dresden, Germany)
Loss-of-function of leptin receptor impairs metabolism in human cardiomyocytes
P1.33 · Pamela Swiatlowska (London, United Kingdom)
Hypertensive pressure mechanosensing triggers transdifferentiation of vascular smooth muscle cells to foam cells
P1.34 · Eleni Tseliou (Salt Lake City, UT, U.S.A.)
Cardiac and serum sphingolipid profiles in myocardial recovery after left ventricular assist device support
P1.35 · Iga M. Walczak (Gdańsk, Poland)
Metabolic benefits and microvascular improvement in heart failure patients using SGLT2 inhibitors
P1.36 · Seon Bu Yang (Seoul, Republic of Korea)
Ubxn4 deficiency aggravates hepatic steatosis in high-fat diet-fed mice
P1.37 · Aaron Jiashuo Zhang (Oxford, United Kingdom)
Insulin resistance blunts hypoxia-induced histone lysine methylation in the heart and upregulates expressions of histone lysine demethylases
P1.38 · Zhenyi Zhao (Orsay, France)
Phenotypic differences of chronic angiotensin II/phenylephrine infusion to C57BL/6J and C57BL/6N mouse substrains
P1.39 · Martin Bahls (Greifswald, Germany)
Exercise exposes dysfunctional immune-metabolic response in heart failure with reduced ejection fraction
P1.40 · Ríona M. Devereux (Oxford, United Kingdom)
Identification of the lipid-protein interactome: a novel chemo-proteomic approach to understand cardiometabolic diseases
P1.41 · Bellina Mushala (Pittsburgh, PA, U.S.A.)
Adropin treatment restores cardiac function and metabolic flexibility in HFpEF
P1.42 · Akshay Shekhar (New York, NY, U.S.A.)
CD36 deficiency accelerates the pathogenesis of pulmonary heart disease
P1.43 · Chloé David (Montréal, Canada)
The vitamin B paradox: unlocking untapped potential in female heart failure therapy
P1.44 · Konstantinos Lekkos (Oxford, United Kingdom)
Oxidative phosphorylation is required for cardiomyocyte re-differentiation and long-term fish heart regeneration
P1.45 · Julie H. Rennison (Cleveland, OH, U.S.A.)
PPARα signaling is increased but expression of proteins that modulate mitochondrial dynamics are decreased in left atrium of patients in atrial fibrillation
P2.1 · Petra Alanova (Praha, Czechia)
HIF-1α and mitochondria in cardioprotection induced by adaptation to chronic hypoxia
P2.2 · Carsten Beets (Stillwater, OK, U.S.A.)
Exploring the interplay of diabetes and influenza infection: The role of the insulin receptor substrate
P2.3 · Charlotte Betus (Montréal, Canada)
Impact of endothelial O-GlcNAcylation in the development and progression of proliferative retinopathy
P2.4 · Martin Bouaud (Nantes, France)
O-GlcNAcylation and adaptation to hypoxia during cardiac development
P2.5 · Nikole Byrne (Graz, Austria)
SIRT5 improves recovery following myocardial ischemia reperfusion injury by limiting H2O2 production
P2.6 · David Yin Cai (Hong Kong, China)
Cardiomyocyte-specific overexpression of GCH1 mitigates HFpEF by reducing oxidative stress via Nrf2 pathway activation
P2.7 · Christine Des Rosiers (Montreal, Canada)
Uncovering heart failure (HF) patient subgroups with distinctive clinical and lipid characteristics within and between cohorts using untargeted plasma lipidomics and machine learning
P2.8 · Gregory Ducker (Salt Lake City, UT, U.S.A.)
MCT1 is required for the uptake and mitochondrial oxidation of lactate in the myocardium
P2.9 · Anna A. Faakye (Oklahoma, OK, U.S.A.)
The pharmacological effect of acetylation in modulating cardiac mitochondrial metabolism
P2.10 · Ludovic Gomez (Bron, France)
Limitation of SERCA2a phosphorylation at the heart of cardioprotection
P2.11 · Giulia Guerra (Turin, Italy)
Unravelling doxorubicin cardiotoxicity through the lens of metabolism: a multi-omics journey across mitochondrial alterations
P2.12 · Eva Guilloteau (Nantes, France)
Is early hyper-O-GlcNAcylation alter placental vascularisation and angiogenesis?
P2.13 · Kylene M. Harold (Oklahoma City, OK, U.S.A.)
Impacts of PFKFB2-mediated glycolytic regulation on cardiac electrophysiology and O-GlcNAcylation are fed state-dependent
P2.14 · Estelle Heyne (Jena, Germany)
Mitochondrial respiratory capacity in patients with dilated versus ischemic cardiomyopathy – an exploratory analysis
P2.15 · Yung-Ting Hsiao (Osaka, Japan)
A brown adipose tissue-derived aging-associated profibrotic protein as a SASP promotes heart fibrosis
P2.16 · Xin Hu (Amsterdam, Netherlands)
Exogenous physiological concentrations of lactate and pyruvate play important roles in intrinsic metabolic pathways of the ex vivo mouse heart
P2.17 · Anu Jose (Saint John, Canada)
Role of lipid phosphate phosphatase 3 in cardiac lipid and mitochondrial homeostasis
P2.18 · Hyoung Kyu Kim (Busan, Republic of Korea)
Cardioprotective Effects of Neopetroside A via GSK-3β Inhibition and Nrf2/NQO1 Activation
P2.19 · Joanna Konieczny (Tromsø, Norway)
Fructose-induced liver steatosis model to study the inter-organ crosstalk on the liver-heart axis
P2.20 · Veronique Lacombe (Stillwater, OK, U.S.A.)
Protein disulfide isomerase improves cardiac and systemic glucose metabolism during diabetes
P2.21 · Susan K. Malone (New York, NY, U.S.A.)
Time-of-day dynamics in cardiometabolic parameters: assessment of cortisol, melatonin, and glucose relationships in adults with prediabetes and short sleep duration
P2.22 · Miranda Nabben (Maastricht, Netherlands)
Sex-based differences in cardiomyocyte physiology: investigating cellular and hormonal influences
P2.23 · Motohiro Nishida (Fukuoka, Japan)
Supersulfide metabolism in cardiac stress resistance
P2.24 · Mariola J. Olkowicz (Gdansk, Poland)
Individuals with heart failure stratified by their left ventricular ejection fraction display distinct lipidomic signatures: insights from the MyoVasc study
P2.25 · Archee Panwar (Edmonton, Canada)
Stimulating myocardial glucose oxidation improves cardiac function in diabetic cardiomyopathic mice
P2.26 · Aleksandra Paterek (Warsaw, Poland)
Epicardial fat transformation in the vicinity of the failing left ventricle in end-stage heart failure with reduced ejection fraction
P2.27 · Noemi Polgar (Honolulu, HI, U.S.A.)
Loss of exocyst function in cardiomyocytes results in heart failure
P2.28 · José Carlos Rivera (Montreal, Canada)
Glia-derived lipid metabolites drive pathological angiogenesis in proliferative retinopathy
P2.29 · Iain Scott (Pittsburgh, PA, U.S.A.)
Cardiac-specific deletion of GCN5L1 promotes fatty liver disease in HFpEF
P2.30 · Mahnaz Shariatzadeh (Maastricht, Netherlands)
Enhancing O-GlcNAcylation as a metabolic intervention in an in vitro model of acute decompensated heart failure
P2.31 · Klaudia Stawarska (Gdansk, Poland)
Radiotherapy-induced metabolic and mitochondrial dysregulation of the heart
P2.32 · Eline Stukkens (Brussels, Belgium)
A novel sex-dependent role for α-tubulin acetylation on Lys40 in diabetic cardiomyopathy development
P2.33 · Nolwenn Tessier (Nantes, France)
O-GlcNAc as a key regulator for survival of babies suffering from congenital heart disease
P2.34 · Amandine Vergnaud (Nantes, France)
Unveiling the critical role of O-GlcNAcylation in cardiac development
P2.35 · Seon Bu Yang (Seoul, Republic of Korea)
RUNX3 negatively regulates agonists induced cardiac fibroblasts differentiation
P2.36 · Joo Mi Yi (Busan, Republic of Korea)
Epigenetic insights into cardiovascular disease: DNA methylation as a potential biomarker for diabetic cardiomyopathy
P2.37 · Liyan Zhang (Edmonton, Canada)
R-2-hydroxyglutarate displays anti-proliferation activity in U87 glioblastoma cells by reducing the Warburg effect
P2.38 · Jie Zheng (Saint Louis, MO, U.S.A.)
Myocardial oxygen extraction is reduced only in severe fibrotic regions in patients with ischemic heart failure
P2.39 · Satoshi Bujo (Cambridge, United Kingdom)
LPLAT7 deficiency impacts cardiomyocyte phospholipid remodeling associated with myocardial dysfunction
P2.40 · Yasutomi Higashikuni (Shimotsuke-shi, Japan)
The DEAD-box RNA helicase Ddx41 contributes to adverse cardiac remodeling in response to pressure overload through modulation of RNA metabolism
P2.41 · Bernadin Ndongson Dongmo (Oslo, Norway)
Phosphodiesterase 2A overexpression prevents atrial fibrillation and conduction dysfunction independently of diastolic dysfunction in a mouse HFpEF model
P2.42 · Louis Berillon (Montreal, Canada)
Endothelial O-GlcNAcylation is crucial for cardiovascular development
P2.43 · Anne D. Hafstad (Tromsø, Norway)
MitoLupus: Heart failure development and mitochondrial dynamics in Systemic Lupus Erythematosus (SLE)
P2.44 · Natasha Nambiar (Berlin, Germany)
The IRE1α arm of the UPR (unfolded protein response) senses lipid stress in cardiac lipotoxicity and engages a novel interactome